Filgotinib exhibits 30-fold greater selectivity for JAK1 over JAK2 [397], In phase II studies for RA (NCT01888874, NCT01888874), higher daily doses effectively controlled disease activity, demonstrating superiority over placebo both as monotherapy and in combination therapy. Here, JAK2 is linked to rheumatoid arthritis.